本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Aura Biosciences, Inc.

6.16
+0.03000.49%
盘后6.160.00000.00%16:44 EDT
成交量:17.67万
成交额:108.06万
市值:3.83亿
市盈率:-3.16
高:6.23
开:6.10
低:5.96
收:6.13
52周最高:12.38
52周最低:4.35
股本:6,211.99万
流通股本:3,525.82万
量比:0.73
换手率:0.50%
股息:- -
股息率:- -
每股收益(TTM):-1.9516
每股收益(LYR):-1.7506
净资产收益率:-55.39%
总资产收益率:-32.14%
市净率:2.19
市盈率(LYR):-3.52

数据加载中...

2024/11/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/13

重要事件披露

Form 8-K - Current report
2024/11/12

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/10/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/17

重要事件披露

Form 8-K - Current report
2024/10/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/27

重要事件披露

Form 8-K - Current report
2024/09/12

重要事件披露

Form 8-K - Current report
2024/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/08

重要事件披露

Form 8-K - Current report
2024/06/21

重要事件披露

Form 8-K - Current report
2024/06/14

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/06/04

重要事件披露

Form 8-K - Current report